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STUDIES OF HYPOXEMIC/ 
REOXYGENATION INJURY: 
WITH AORTIC CLAMPING 
XIII. Interaction between 
oxygen tension and 
cardioplegic omposition 
in limiting nitric oxide 
production and oxidant 
damage 
This study tests the interaction between oxygen tension and cardioplegic 
composition on nitric oxide production and oxidant damage during reoxy- 
genation of previously cyanotic hearts. Of 35 Duroc-Yorkshire piglets (2 to 
3 weeks, 3 to 5 kg), six underwent 30 minutes of blood cardioplegic arrest 
with hyperoxemic (oxygen tension about 400 mm Hg), hypocalcemic, 
alkalotic, glutamate/aspartate blood cardioplegic solution during 1 hour 
of cardiopulmonary bypass without hypoxemia (control). Twenty.nine 
others were subjected to up to 120 minutes of ventilator hypoxemia (oxygen 
tension about 25 mm Hg) before reoxygenation on CPB. To simulate 
routine clinical management, nine piglets underwent uncontrolled cardiac 
reoxygenation, whereby cardiopulmonary bypass was started at oxygen 
tension of about 400 mm Hg followed by the aforementioned blood 
cardioplegic protocol 5 minutes later. All 20 other piglets underwent 
controlled cardiac reoxygenation, whereby cardiopulmonary bypass was 
started at the ambient oxygen tension (about 25 mm Hg), and reoxygen- 
ation was delayed until blood cardioplegia was given. The blood cardiople- 
gia solution was kept normoxemic (oxygen tension about 100 mm Hg) in 10 
piglets and made hyperoxemic (oxygen tension about 400 mm Hg) in 10 
others. The cardioplegic composition was also varied so that the cardiople- 
gic solution in each subgroup contained either KCI only (30 mEq/L) or 
components that theoretically inhibit nitric oxide synthase by including 
hypocalcemia, lkalosis, and glutamate/aspartate. Function (end-systolic 
elastance) and myocardial nitric oxide production, conjugated iene pro- 
duction, and antioxidant reserve capacity were measured. Blood cardiople- 
gic arrest without hypoxemia did not cause myocardial nitric oxide or 
conjugated iene production, reduce antioxidant reserve capacity, or change 
left ventricular functional recovery. In contrast, uncontrolled cardiac reoxygen- 
alion raised nitric oxide and conjugated iene production 19- and 13-fold, 
respectively (p < 0.05 vs control), reduced antioxidant reserve capacity 40%, 
and contractility recovered only 21% of control evels. After controlled cardiac 
reoxygenation at oxygen tension about 400 mm Hg with cardioplegic solution 
containing KCI only, nitric oxide and conjugated iene production rose 
16- and 12-fold, respectively (p < 0.05 vs control), and contractility 
recovered only 43% ± 5%. Normoxemic (oxygen tension of about 100 mm 
Hg) controlled cardiac reoxygenation with the same solution reduced 
nitric oxide and conjugated diene production 85% and 71%, and contractile 
recovery rose to 55% ± 7% (p < 0.05 vs uncontrolled reoxygenation). In 
comparison, controlled cardiac reoxygenation with an oxygen tension 
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of about 400 mm Hg hypocalcemic, alkalotic, glutamate/aspartate blood cardioplegic 
solution reduced nitric oxide and conjugated diene production 85% and 62%, 
respectively, and contractility recovered 63% -- 4% (p < 0.05 vs KCI only). 
Normoxemic delivery of this solution resulted in negligible nitric oxide and 
conjugated iene production and 83% + 8% recovery of contractility (t7 < 0.05 vs all 
other groups). These data show correlation between nitric oxide production during 
initial reoxygenation and the extent of oxidant damage (i.e., conjugated diene 
production) and link functional recovery to suppression of excessive nitric oxide 
production and limitation of lipid peroxidation by the interaction of oxygen tension 
and cardioplegic omposition during initial reoxygenation. (J THORAC CARDIOVASC 
SURG 1995;110:1274-86) 
T he pathophysiology of ischemic/reperfusion dam- age differs from that of hypoxemic/reoxygenation 
injury in the immature heart. 1'2 Previous studies 
show that control of the initial conditions of reper- 
fusion and composition of the reperfusate blood 
cardioplegic solution limits cardiac damage when 
blood supply is restored after ischemia. 3'4 We have 
documented that a similar blood cardioplegic strat- 
egy limits oxidant damage in the setting of hypox- 
emia/reoxygenation.5, 6 It is now recognized that 
myocardial damage develops when molecular oxy- 
gen is reintroduced when extracorporeal circulation 
is started in hypoxemic hearts, and (1) is oxygen 
tension (P02) dependent, 7' s (2) occurs whether eoxy- 
genation is gradual or sudden, 7'9 (3) can be limited by 
delaying reoxygenation u til the aorta is clamped and 
blood cardioplegia is delivered shortly after starting 
cardiopulmonary b pass (CPB), 6' 7 and (4) is caused in 
part by production of reactive oxygen intermediates 
via the heretofore unrecognized L-arginine-nitric ox- 
ide (.NO) pathwayJ °-12 
Several cardioplegic omponents that are cardio- 
protective for both reperfusion and reoxygenation 
damage also limit .NO production; constitutive .NO 
synthase activity is Po 2 calcium-calmodulin depen- 
dent, 13 its activity is down-regulated byalkalosis and 
the reduced shear stress accompanying gentle reper- 
fusion pressure, 14 and glutamate and aspartate limit 
L-arginine transport. 15-1s 
This study was undertaken i cyanotic hearts under- 
going controlled cardiac reoxygenation, whereby CPB 
was initiated at the ambient hypoxemic Po 2 and reoxy- 
genation was delayed until the cardioplegic solution 
was administered. The intent was to distinguish the 
interaction between Po 2 and cardioplegic constituents 
in limiting -NO synthase activity (hypocalcemia, lka- 
losis, and glutamate/aspartate). The results show 
that avoiding excessive .NO production correlates 
with decreased oxidant damage and offsets the 
contractile impairment hat otherwise follows un- 
controlled cardiac reoxygenation. 
Material and methods 
Experimental model. Thirty-five immature, 2- to 3-week- 
old Duroc-Yorkshire piglets (3 to 5 kg) were premedicated 
with 0.5 rng/kg diazepam intramuscularly, anesthetized with 
30 mg/kg pentobarbital intraperitoneally followed by 5 mg/kg 
intravenously each hour, and the lungs ventilated on a 
volume-limited respirator (Servo 900D, Siemens-Elema, 
Solna, Sweden) via a tracheostomy. All animals received 
humane care in compliance with the "Principles of Labora- 
tory Animal Care" formulated by the National Society for 
Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy of 
Sciences, published by the National Institutes of Health 
(NIH Publication No. 86-23, revised 1985). The surgical 
preparation, including vessel cannulation for CPB and place- 
ment for monitoring and blood sampling, was similar to that 
reported previouslyJ 9
Physiologic and biochemical determinations. Hemody- 
namic measurements were made before the start of 
hypoxemia (control), every 15 minutes during hypoxemia, 
and 15 and 30 minutes after the discontinuation f CPB. 
Cardiac output was determined by duplicate injections of 
1 ml of 4°C cold saline solution into a central venous 
catheter. Cardiac index (CI), systemic vascular resistance 
(SVRI), pulmonary vascular resistance index (PVRI), and 
left ventricular stroke work index (LV-SWI) were calcu- 
lated with the following equations: 
CI (ml/min/kg) = CO/body weight (kg) 
SVRI (rnmHg • rain • L-1 . kg) = (MAP 
- CVP) (ram Hg) • CO 1 (L/rain) • BW (kg) 
PVRI (mm Hg" rain. L -1- kg) = (PAP - LAP) 
(ram Hg). CO -1 (ml/min) • body weight (kg) 
LVSWI (g. m/kg) = (MAP - LAP) × CO (ml/min) 
× 0.0136/(HR × bodyweight [kg]) 
where MAP is mean aortic pressure, PAP is mean pulmo- 
nary artery pressure, LAP is mean left atrial pressure, 
1276 Ihnken et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1995 
CVP is central venous pressure, CO is cardiac output in 
milliliters per minute, and HR is heart rate. 
Myocardial performance. LV pressure and conduc- 
tance catheter signals were amplified and digitalized to 
inscribe LV pressure-volume loops after correction for 
tissue conductance. 2° The series of pressure-volume loops 
were generated under varying loading conditions by tran- 
sient occlusion of the inferior vena cava during a 7-second 
period of apnea. Measurements were made before hypox- 
emia (control) and 30 minutes after discontinuation of 
CPB. The end-systolic pressure volume relationship 
(ESPVR) was analyzed by an interactive videographics 
data analysis computer program (Spectrum, Bowman 
Gray School of Medicine, Winston-Salem, N.C.) on an 
386/33 MHz IBM computer (IBM, Armonk, N.Y.), and 
LV performance was described as the slope of linear 
regression (end-systolic elastance [Ees]), as described previ- 
ously.a1.22 Myocardial function before and after CPB was 
also evaluated with Starling curves by infusing CPB blood 
into the inferior vena cava at 5 ml/min/kg while recording 
CO, MAP, and LAP. 
Myocardial .NO production..NO was determined in 
plasma by reconverting its oxidation N-products nitrite 
(NO2-) and nitrate (NO3-), to .NO in measuring 
chemiluminescence after .NO reacts with ozone using 
nitrogen oxide analyzer (Model 2108, DASIBI Environ- 
mental Corporation, Glendale, Calif.)Y Blood samples 
were taken from the coronary perfusate (blood cardio- 
plegia) and coronary effluent (coronary sinus blood) to 
assess arteriovenous differences in -NO during induc- 
tion of blood cardioplegia. Production of .NO is mea- 
sured by the .NO production = CBF × (V - A)/100 gm 
heart weight where A and V are the respective concen- 
trations o f -NO measured in the aortic and coronary 
sinus blood during cardioplegic delivery when the car- 
dioplegic solution was administered in a fixed coronary 
blood flow rate (CBF) by calibrated roller pump as 
described under control studies. 
Myocardial oxidant injury 
Myocardial conjugated diene production. Additional ali- 
quots of coronary artery perfusate (blood cardioplegia) 
and coronary venous effluent were sampled to determine 
conjugated iene production. Samples were centrifuged 
immediately for 5 minutes at 1000g. Plasma was stored in 
liquid nitrogen for later analysis of conjugated ienes as 
described previously. 24 Conjugated iene production was 
calculated by the formula: CBF x (V - A)/100 gm heart 
weight where A and V are the concentrations of conju- 
gated dienes in the blood cardioplegic perfusate and 
coronary sinus effluent respectively and CBF is the coro- 
nary blood flow rate in milliliters per minute. 
Antioxidant reserve capacity. The myocardial antioxi- 
dant state was assessed by determining in vitro lipid 
per.oxidation in cardiac tissue that was homogenized 
and incubated with t-butylhydroperoxide at concentra- 
tions varying from 0 to 4 mmol/L for 30 minutes at 
37°C by the method of Godin and coworkers 25 de- 
scribed previously. 
Experimental groups 
Nonhypoxernic studies 
BLOOD CARDIOPLEGIA WITHOUT HYPOXEMIA. Six nor- 
moxemic piglets (Po 2 of about 100 mm HE) underwent 60 
minutes of hyperoxemic CPB at a Po 2 of about 400 mm 
Hg without preceding hypoxemia. After 5 minutes of 
CPB, they underwent 30 minutes of aortic clamping with 
a hyperoxemic blood cardioplegic solution that was devel- 
oped experimentally 26-2s and is used clinically. 29' 30 The 
blood cardioplegic management protocol included warm 
cardioplegia (37 ° C) for 3 minutes followed by cold car- 
dioplegia for 2 minutes (4 ° C) and a 3-minute warm 
infusion just before aortic unclamping. Infusion rate was 
regulated initially by calibrated pump at 10 ml/min/kg to 
produce arrest and 5 ml/min/kg thereafter with an aortic 
pressure averaging about 50 mm HE. CPB was discontin- 
ued 25 minutes after aortic unclamping, and functional and 
biochemical measurement were made 30 minutes later. This 
CPB protocol was followed in all subsequent s udies when 
hypoxemic piglets were reoxygenated on CPB. 
Hypoxemia/reoxygenation studies 
Twenty-nine piglets were made hypoxemic by lowering 
inspired O2 to 6% to 7% to reduce Po 2 to about 25 mm 
Hg for up to 120 minutes before reoxygenation on CPB 
for 60 minutes. Extracorporeal circulation was begun 
before 120 minutes if mean arterial pressure fell below 30 
mm Hg or arterial pH could not be kept above 7.35 by infusing 
NaHCO 3 (1 mEq/kg) by bolus injection. 
UNCONTROLLED CARDIAC REOXYGENATION. Nine piglets 
were reoxygenated bythe conventional c inical procedure 
of starting CPB at Po~ about 400 mm Hg and underwent 
a 30-minute interval of aortic clamping with the use of the 
aforementioned blood cardioplegic protocol. 
CONTROLLED CARDIAC REOXGYENATION. Twenty hypox- 
emic piglets were placed on CPB using a hypoxemic P% of 
about 25 nun Hg prime in the CPB circuit to match the 
pre-CPB Po 2. This level of hypoxemia was produced by adjust- 
hag the blend of N 2 and 02 in the CPB circuit. All underwent 
controlled cardiac reoxygenation, whereby the increase in Poa in 
the CPB circuit and blood cardioplegic solution was delayed 
until the aorta was damped and blood cardioplegia was given 5 
minutes after CPB was started. All piglets underwent 30 min- 
utes of aortic clamping using the aforementioned blood car- 
dioplegic and CPB regimen. The Po 2 in the CPB and blood 
cardioplegic solution and blood cardioplegic formulation were 
adjusted as described below. 
Blood cardioplegia with KCI only 
NORMOXEMIC REOXYGENATION. Five piglets received 
normoxemic blood cardioplegia (Po 2 about 100 mm HE) 
containing only KC1 (30 mEq/L). 
HYPEROXEMIC REOXYGENATION. Five other piglets re- 
ceived hyperoxemic cardioplegia (Po2 about 400 mm HE) 
containing only KC1 (30 mEq/L). 
Blood cardioplegia with glutamate/aspartate, hypocalce- 
mia, and alkalosis 
NORMOXEMIC REOXYOENATION. Five piglets received 
normoexcmic (Po 2 about 100 mm HE) blood cardioplegia 
containing the hypocalcemic, alkalotic, glutamate/aspar- 
tate additives used in control studies. 
HYPEROXEMIC REOXYGENATION. Five piglets received a 
hyperoxemic (Po a about 400 mm HE) blood cardioplegic 
solution containing the aforementioned a ditives. 
Arterial Po 2 was raised to about 400 mm Hg immedi- 
ately after aortic unclamping in piglets undergoing nor- 
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Fig. 1. Percent of recovery of Ees in control studies with CPB without hypoxemia (no hypoxemia) nd 
after uncontrolled reoxygenation (Re02). 
moxemic reoxygenation. Mean arterial blood pressure was 
adjusted to 60 to 70 mm Hg after cardiac contraction 
resumed. Arterial blood gases and electrolytes were re- 
stored to normal levels before final measurements of 
biochemical variables and contractile function were made 
30 minutes after CPB. Hearts were then arrested with cold 
(4 ° C) blood cardioplegia (KC1 30 mEq/L) to stop metab- 
olism, and a transmural LV biopsy was obtained (about 
200 mg of tissue). The subendocardial portion was sepa- 
rated, frozen quickly in liquid nitrQgen, and stored for 
biochemical nalyses. 
Statistics. Data were analyzed with the use of the 
StatView V2.0 program (Abacus Concepts Inc., Berkeley, 
Calif.) on a Macintosh IIci computer (Apple, Inc., Cuper- 
tino, Calif.). Analysis of variance was used for intergroup 
comparison, and the paired Student  test was used for 
comparison of variables within experimental groups. The 
relationship between functional impairment (percent Ees) 
and lipid peroxidation (conjugated dienes) was tested by 
linear regression analysis. Differences were considered 
significant at the probability level ofp < 0.05. Group data 
were expressed as mean plus or minus standard error of 
the mean. 
Results 
Hemodynamic results. Hypoxemia caused 
tachycardia (heart rate increased from 170 _+ 10 
to 206 _+ 15 beats/min), pulmonary vasoconstric- 
tion (PVRI increased 120% + 21%), peripheral 
vasodilatation (SVRI) decreased 34% +_ 12%, and 
an initial increase in cardiac output occurred 
(28% _+ 8%). There was no statistically significant 
difference in bolus NaHCO 3 injections (averaging 
1 to 2 per piglet) or in the duration of hypoxemia 
among the groups, as ventilator hypoxemia was 
tolerated for an average of 75, 63, 65, 64, and 63 
minutes, respectively. 
All piglets could support he circulation after CPB 
was discontinued and achieved normal to near- 
normal cardiac output after volume infusion. A 
higher LAP was needed to maintain the same 
LVSWI after either uncontrolled reoxygenation or
hyperoxemic controlled reoxygenation with KC1 car- 
dioplegia than after normoxemic reoxygenation; o 
further augmentation of stroke work index by vol- 
ume infusion occurred after LAP was more than 8 to 
10 mm Hg. 
LVcontractility. Myocardial performance was un- 
affected in nonhypoxemic piglets undergoing 1 hour 
of hyperoxemic CPB and blood cardioplegia. In 
contrast, uncontrolled reoxygenation with the same 
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Fig. 2. Percent recovery of Ees after controlled cardiac reoxygenation with KC1 blood cardioplegia (KCl 
only) or with blood cardioplegia containing low calcium (low Ca++), glutamate/aspartate (G/A), and 
alkalosis (pH 7.6). 
CPB and blood cardioplegic solution was associated 
with only 21% recovery of LV Ees (Fig. 1). Con- 
trolled cardiac reoxygenation improved contractile 
recovery in all studies, with the extent of improve- 
ment related closely to the interaction between Po 2 
and blood cardioplegic omposition. LV Ees in- 
creased to 43% + 5% when reoxygenation was 
delayed until Po2 about 400 mm Hg blood cardio- 
plegia with KC1 only was used for myocardial man- 
agement during aortic clamping, and rose to 55% __+ 
7% when Po2 was kept about t00 mm Hg. 
Further improvement to 63% _+ 4% return of 
contractile function occurred when the Po2 of about 
400 mm Hg (Fig. 2) cardioplegic solution contained 
glutamate/aspartate, hypocalcemia, nd alkalosis, 
and rose to 83% _+ 8% at Po 2 of about 100 mm Hg 
(p < 0.05 vs KC1 only). 
Biochemistry results 
Nitric oxide production. Uncontrolled cardiac 
reoxygenation with the CPB circuit primed with 
blood at Po 2 of about 400 mm Hg caused a 19-fold 
increase in .NO production compared with control 
nonhypoxemic piglets given the same hyperoxemic 
blood cardioplegic solution (p < 0.05) (Fig. 3). A 
similarly pronounced .NO production (16-fold in- 
crease, p < 0.05) occurred after controlled cardiac 
reoxygenation when the blood cardioplegic solution 
was delivered at Po 2 about 400 mm Hg and con- 
tained only KC1 (Fig. 4). In contrast, .NO increased 
only threefold when the KC1 blood cardioplegic 
solution was made normoxemic (p < 0.05 vs uncon- 
trolled reoxygenation). Supplementation of the 
blood cardioplegic formulation with glutamate/as- 
partate, hypocalcemia, nd alkalosis caused only a 
twofold increase in .NO production despite Po2 of 
about 400 mm Hg, and "NO production was compa- 
rable with control values when this cardioplegic 
solution was delivered at aPo 2 of about 100 mm Hg 
(p < 0.05 vs uncontrolled reoxygenation). 
Conjugated diene production. The aforemen- 
tioned changes in .NO production were paralleled 
by changes in conjugated ienes, because uncon- 
trolled cardiac reoxygenation caused a 13-fold in- 
crease in conjugated diene levels (from 3 _+ 2 to 42 
+ 4 A233 nm/min/100 g) (Fig. 5), which was un- 
changed by controlled cardiac reoxygenation when 
the Po 2 about 400 mm Hg cardioplegic solution 
contained KC1 only (39 + 11 A233 nm/min/100 g, 
p > 0.05 vs control). Conjugated iene production 
was reduced 71% (to 12 _+ 6) when the KC1 car- 
diop!egic solution was delivered normoxemically at 
Po2 about 100 mm Hg (p < 0.05 vs uncontrolled 
reoxygenation). A comparable reduction (62%) in 
conjugated iene levels occurred espite a Po 2 of 
about 400 mm Hg reoxygenation when the car- 
dioplegic formulation contained constituents hat 
inhibit NO synthase (16 _+ 8 nmol, p < 0.05 vs 
uncontrolled reoxygenation); Normoxemic delivery 
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Fig. 3. Myocardial .NO production during blood cardioplegic induction in control studies of CPB without 
hypoxemia and after uncontrolled reoxygenation (ReO2). 
of this formulation resulted in conjugated iene 
production that was comparable with nonhypoxemic 
piglets (Fig. 6, p < 0.05). 
Antioxidant reserve capacity. Uncontrolled cardiac 
reoxygenation reduced antioxidant reserve capacity 
(AORC) 40% (compared with control animals with- 
out hypoxemia, p < 0.05). Mild but insignificant 
reductions in AORC occurred also when controlled 
cardiac reoxygenation was managed with blood car- 
dioplegic solution containing KC1 only, because 
AORC was reduced 18% and 17%, respectively, 
with hyperoxemic and normoxemic management 
(compared with the control group). Controlled car- 
diac reoxygenation with hyperoxemi c blood cardio- 
plegia containing potential -NO synthase inhibitors 
was also associated with a 17% reduction in AORC 
compared with the control group, whereas normox- 
emic management a Po5 about 100 mm Hg with the 
same solution maintained normal AORC values and 
improved AORC 36% compared with uncontrolled 
reoxygenation (p < 0.05). 
Discussion 
This study provides further evidence that reoxy- 
genation injury causes dysfunction after CPB and 
emphasizes a linkage between the interaction of Po 2 
and blood cardioplegia composition i affecting .NO 
production and biochemical nd functional evidence 
of oxidant damage. These data confirm the potential 
cytotoxic role of .NO reported by others. 12' 31-33 The 
detrimental effects of reoxygenation nullified the 
cardioprotective action of an otherwise safe blood 
cardioplegic myocardial management protocol, and 
damage was limited when reintroduction of molec- 
ular oxygen was delayed until the heart was given a 
normoxemic blood cardioplegic solution developed 
originally to treat reperfusion damage. 3 The effects 
of this strategy seemed in part related to how the 
control of Po 2 and blood cardioplegic omposition 
altered the L-arginine-.NO pathway. 
Role of NO. Recent findings confirm that -NO 
may produce myocardial contractile dysfunc- 
tion.10, 31, 33 The present report quantifies a substan- 
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Fig. 4. Myocardial .NO production during cardioplegic nduction after controlled cardiac reoxygenation 
with KC1 blood cardioplegia (KCl only) or with blood cardioplegia containing low calcium (low Ca ++) 
glutamate/aspartate (G/A), and alkalosis (pH 7.6). 
tially greater production of .NO after reoxygenation 
than our previous report, 1° because we determined 
actual production rates of nitrite and nitrate rather 
than isolated serum nitrite levels alone. Myocardial 
• NO production during reoxygenation correlated 
with the severity of oxidant injury because a sup- 
pression of .NO Production by controlling blood 
cardioplegic Po 2 composition reduced lipid peroxi- 
dation and improved myocardial function. Potential 
sources of-NO include the endothelium, myocytes, 
endocardium, and mitochondria, 13'34-36 but this 
study does not distinguish their relative contribu- 
tions to the observed amage or examine the extent 
of suppression of :NO production by individual 
blood cardioplegic solution elements. 
Arginine is a biochemical precursor of-NO that 
controls endothelial-derived relaxation..NO also 
inhibits vascular adherence of neutrophils and plate- 
lets, which perhaps accounts for the salutary effects 
of L-arginine in the ischemic/reperfusion model, 37 
where blood flow is stagnant and neutrophils be- 
come adherent during ischemia nd activated uring 
reperfusion. 38 Conversely, L-arginine accelerates 
re0xygenation damage in the in vivo hypoxemic 
model in which CBF is high and neutrophil adher- 
ence is less likely. 1°' 11 Clearly, a balance between 
the physiologic and pathologic effects of .NO must 
be established. Furthermore, lactate accumulation 
may down-regulate metabolism during ischemia nd 
provide reducing equivalents during reperfusion, 39
whereas the high coronary flow during hypoxemia 
prevents lactage buildup. 
These in vivo findings are consistent with recent in 
vitro studies showing that the maximum velocity 
Vma x of constitutive "NO synthase is related to 
oxygen tension. 4° .NO production rose markedly in 
hypoxemic hearts reoxygenated with a Po 2 of about 
400 mm Hg blood cardioplegia with K+ only, 
whereas .NO production and subsequent myocardial 
dysfunction were reduced markedly after controlled 
reoxygenation with a hyperoxemic cardioplegic so- 
lution with components hat reduced .NO synthase 
activity. Normal .NO production, minimal impair- 
ment of AORC, and 83% functional recovery fol- 
lowed controlled reoxygenation with a Po 2 of about 
100 mm Hg cardioplegic solution of similar compo- 
sition. We speculate that the excess of .NO reacts 
with superoxide anion (02-) and generates the 
intermediate peroxynitrite (OONO-), which de- 
composes to generate highly toxic 02 and N 2 inter- 
mediates that cause lipid peroxidation. 41' 42 
Pronounced .NO production after abrupt uncon- 
trolled reoxygenation may result in adverse bio- 
chemical reactions besides those related to per- 
oxynitrite formation..NO mediates iron release 
from ferritin, the protein that stores excess intracel- 
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Fig. 5. Myocardial conjugated iene production during cardioplegic nduction in control studies of CPB 
without hypoxemia, nd after uncontrolled reoxygenation (Re02). 
lular iron, 43 so that .NO may participate in the 
Haber-Weiss reaction by mechanisms that were not 
appreciated previously. This observation is under- 
scored by studies showing that deferoxamine, an 
iron chelator, prevents reperfusion- and reoxygen- 
ation-related myocardial damage. 44-46 
These observations imply the possibility of an .NO 
paradox much like this 028 and calcium paradox, s 
whereby a substance responsible for modulating 
several physiologic functions (i.e., vascular tone, 
white blood cell, and platelet adherence) may be- 
come deleterious when produced in high concentra- 
tions upon reoxygenation. The confusion over how 
the same substance can be both salutary and detri- 
mental is resolved by recognizing that substances 
may have different actions during versus after reoxy- 
genation. 
Role of Po2. CPB in normoxemic and hypoxemic 
infants is initiated usually at high Po 2 (about 400 
mm Hg) without consideration of the possible cyto- 
toxic effects of abrupt hyperoxemia. This study 
shows that only 5 minutes of uncontrolled reoxygen- 
ation by hyperoxemic CPB produced sufficient dam- 
age to nullify the benefits of blood cardioplegia. 
Free radical generation and subsequent myocardial 
injury after reoxygenation are proportionate to 
PO2, 47 and normoxemic reoxygenation is neuropro- 
tective in hypoxemic neuronal cells. 4s Gradual 
reoxygenation without blood cardioplegia reduces 
damage only negligibly when Po 2 is raised to Po 2 
about 400 mm Hg over a 1-hour period. 7We suspect 
that delaying reoxygenation avoided the burst of 
• NO and O2 associated with abrupt reoxygenation, 
because CPB initiated at hypoxemic Po 2 about 25 
mm Hg followed by reoxygenation with normoxemic 
blood cardioplegia resulted in negligible excessive 
• NO production, avoided lipid peroxidation, and 
preserved AORC when the blood cardioplegic for- 
mulation down-regulated .NO synthase activity. 
Controlled cardiac reoxygenation with blood cardio- 
plegia containing KC1 only produced only limited 
recovery. The importance of the interaction of Po 2 
and blood cardioplegic omposition was amplified 
by the finding that a Po 2 about 400 mm Hg blood 
cardioplegic formulation that down-regulated -NO 
synthase activity reduced .NO production and anti- 
oxidant injury more than a Po 2 about 100 mm Hg 
formulation containing KC1 only (Figs. 3 through 6). 
Controlled cardiac reoxygenation with blood car- 
dioplegia. The substrate-enriched blood cardiople- 
gic solution used in these studies was developed 
experimentally asa metabolic way to actively resus- 
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Fig. 6. Myocardial conjugated iene (CD) production during cardioplegic induction after controlled 
cardiac reoxygenation with KC1 blood cardioplegia (KCl only) or blood cardioplegia containing low calcium 
(low CA++), glutamate/aspartate (G/A), and alkalosis (pH 7.6). 
citate energy-depleted hearts 4' 49, 50 and has been 
used in high-risk adult and pediatric patients. TM 52 
This study confirms its safety in non-hypoxemic 
control piglets and substantiated that only 5 minutes 
of uncontrolled reoxygenation offsets its metabolic 
and functional benefits. Our protocols were cardiac 
directed and did not deal with reoxygenation dam- 
age reported to affect other organs (i.e., lung and 
liver).39, 47, 53-55 The near-complete myocardial func- 
tional recovery after controlled cardiac reoxygenation 
is consistent with previous observations in which 
controlled reperfusion was used after regional and 
global ischemia. 3'4'3° We speculate that several 
aspects of controlled cardiac reoxygenation with 
blood cardioplegia limited reoxygenation i jury by 
actions enumerated previously 3 and by some re- 
cently defined mechanisms described below. 
Normothermie potassium arrest with hypocalee- 
mic, alkalotic blood. The importance of initiating 
reoxygenation in the normothermically arrested 
state is underscored by the finding that reoxygen- 
ation hypercontraction a d sarcolemmal disruption 
can be prevented by temporary contractile block- 
ade. 56 This suggests that some of the limited energy 
produced during initial reoxygenation is used to 
normalize cytosolic Ca + +, presumably by improving 
the Na + - Ca ++ exchange. 57Functional recovery 
after controlled cardiac reoxygenation f blood car- 
dioplegia containing KC1 only was inferior to that 
achieved when NO synthase was down-regulated by
the other formulation components (Fig. 4). 
Recent studies link reoxygenation to intracellular 
calcium loading and membrane damage. 57 Hypocal- 
cemic reoxygenation presumably decreases mito- 
chondrial calcium loading and avoids consequent 
impairment of mitochondrial and energy produc- 
tion. 5s Hypocalcemia may also limit activation of 
phospholipases, which degrade membrane phospho- 
lipids and slow the release of reactive oxygen inter- 
mediates via the arachidonic and xanthine oxidase 
pathways. Constitutive .NO synthase is Ca++/calm- 
odulin dependent, so that decreasing extracellular 
Ca ++ attenuates activation of both endothelial and 
endocardial .NO synthase and reduces -NO produc- 
tion.13, 36 Reperfusion alkalosis also favors inactiva- 
tion of .NO by catalyzing its oxidation to inorganic 
nitrate, because .NO is most stable at acidotic pH. 59 
Glutamate/aspartate supplementation. Both hy- 
poxemia and ischemia deplete eytosolic oncentra- 
tions of key precursors of Krebs' cycle intermediates 
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(glutamate and aspartate), thus reducing their avail- 
ability for optimal tricarboxylic acid function on 
reoxygenation.60, 61 Their replenishment in previ- 
ously hypoxemic or ischemic heart may restore 
near-normal function, presumably via improved en- 
ergy metabolism. 62-64 Glutamate and aspartate may 
also affect the L-arginine-.NO pathway via their 
conversion to glutamine. Arginine uptake is essen- 
tial for .NO synthesis, and is regulated by the 
cationic amino acid transport system that can be 
inhibited by L-glutamine and neutral amino ac- 
ids.16, 17 Glutamine synthetase which is present in 
cardiac muscle, converts glutamic acid to L-glu- 
tamine, iv and L-glutamine issynthesized from aspar- 
tate via aspartate amino transferaseJ 8 These obser- 
vations imply that glutamate and aspartate may 
inhibit L-arginine transport and subsequent "NO 
production via their conversion to L-glutamine, in 
addition to their effect on cardiac energy metabo- 
lism. 
Reduced reperfusion pressure. Reducing coronary 
artery pressure during reperfusion improves endo- 
thelial-dependent function. 65 This was attributed to 
a reduction in mechanical damage to vulnerable 
endothelial cells, but endothelium-derived .NO is 
linked closely to shear stress, ~4 so that decreasing 
shear stress by gentle reperfusion may limit the -NO 
that is generated. 
Po 2 in blood cardioplegia. We showed previously 
that lowering Po 2 in the CPB circuit reduced reoxy- 
genation injury minimally without blood cardiople- 
gia if the end point was hyperoxemic at Po 2 about 
400 mm Hg. 7 The present studies indicate that blood 
cardioplegic solution (P02) may influence the effec- 
tiveness of different factors in the blood cardioplegic 
strategy, because O~- and .NO production are Po 2 
dependent.40, 47 Hyperoxemic blood cardioplegia is
probably never needed, because normoxemia (Po 2 
about 100 mm Hg) provides near complete 02 
saturation and 0 2 demands are negligible in the 
arrested ecompressed heart. 66 This concept is sup- 
ported by the superior results obtained with nor- 
moxemic versus hyperoxemic blood cardioplegic 
management s rategy with blood cardioplegic solu- 
tions containing either KC1 only or with constituents 
that reduce .NO synthase activity. 
Clinical implications. These data suggest that 
"unintended" cardiac reoxygenation i jury that fol- 
lows conventional institution of hyperoxemic CPB 
can be reduced by delaying reoxygenation u til the 
aorta is clamped and a blood cardioplegic solution is 
delivered that reduces .NO overproduction and ox- 
idant injury. The pre-CPB dysfunction that charac- 
terized this acutely hypoxemic model is rare in 
patients with compensated cyanosis, but its inci- 
dence was similar in all experimental groups. Re- 
covery occurred only in piglets undergoing con- 
trolled cardiac reoxygenation a d was proportionate 
to the reduction of .NO production and oxidant 
damage. The extent of functional recovery may have 
been underestimated in all studies by the brief 
post-CPB observation period and raising Po 2 to 400 
mm Hg after CPB was stopped. 
Similar changes in antioxidants levels, lipid per- 
oxidation, and functional depression are reported in 
cyanotic infants placed on CPB for cardiac re- 
pair.7, 67-72 Reduced systolic function, which may 
progress to "cardiac stun," occurs without surgical 
ischemia 7,73-74 in cyanotic infants who undergo ex- 
tracorporeal membrane oxygenation for respiratory 
failure. All piglets could be weaned from CPB, but 
our findings of depressed function (exposed by 
testing functional reserve) may explain why inotro- 
pic support is often needed after surgery in cyanotic 
children. 
Our results suggest hat altering routine tech- 
niques of conventional CPB may limit reoxygen- 
ation damage. Initiation of CPB at the ambient 
hypoxemic Po2 reduces .NO production and would 
likely be safe because the flow rate in the extracor- 
poreal circuit could be augmented to ensure 02 
delivery when bypass is started. Furthermore, nor- 
moxemic initiation of CPB at Po2 of about 100 mm 
Hg ensures about 99% oxygen saturation without 
adjustment of CPB flow. It is unlikely that hyperox- 
emic CPB is ever needed intraoperatively or post- 
operatively because Po2 > 100 to 150 mm Hg 
increases 0 2 content negligibly. The methods of 
providing controlled cardiac reoxygenation used in 
this study are available in routine practice and can 
hopefully improve clinical outcome if our results are 
reproduced by others. 
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